• Planned succession of Werfen Chief Executive Officer
• Alejandro Risso to succeed Carlos Pascual

Werfen today announced the planned succession of its CEO, Carlos Pascual. He and the Board of Directors have agreed that he will step down after 37 years with the company, effective April 30, 2025. He will remain in his role until then to ensure a seamless transition.

Werfen’s Board of Directors also named Alejandro Risso, currently President, Clinical Diagnostics at Thermo Fisher Scientific Inc., to succeed Carlos Pascual, effective May 1, 2025. Alejandro Risso will also join the Board of Directors.

Carlos Pascual has served with great distinction, driving significant innovations and accomplishments across a range of senior roles.

During his 12-year tenure as CEO, Werfen has:

• Increased its sales from €800 million to €2.1 billion;
• Expanded its workforce from 3,300 to more than 7,000;
• Added four specialized clinical areas to its business line portfolio: Patient Blood Management, Whole Blood Hemostasis, Transfusion, and Transplant.
  This has solidified Werfen’s position as a global leader in specialized diagnostics, placing it among the top 10 in-vitro diagnostics companies.
• Unified under the slogan One Company, One Team.

Carlos Pascual said, “Being a part of Werfen has been a true honor and privilege. I’m so proud of our company’s incredible accomplishments and to have helped to build the most talented, dedicated, and passionate team in the industry. With the support of the Rubiralta family, the Board of Directors, and our more than 7,000 incredibly talented employees, we have transformed Werfen together, and we have set new standards for excellence and innovation.”

Werfen Chairman Marc Rubiralta said, “Carlos embodies our values and leaves an indelible mark on all of us. His most significant contributions include helping to shape our values through his daily example. The impact of his approach to business, life, and people is an invaluable lesson for everyone.”

He added, “As we look to the future, I’m very excited about the new era we are starting. Together, under Alejandro’s leadership, we will build upon Werfen’s great and solid foundation and continue to evolve for an even brighter future ahead.

Alejandro Risso said, “I’m honored to succeed Carlos as Werfen’s CEO. He has led the company to record results over the last 12 years and has done so with humility, exceptional character, and a service mindset. I’m humbled by the confidence that Marc and the Board of Directors placed in me. My belief in supporting patients through innovative specialized diagnostics will continue to guide Werfen for many years to come.”

Werfen
Founded in 1966, Werfen is a developer, manufacturer, and worldwide distributor of specialized diagnostic instruments, related reagents, automation work cells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The company's business lines include Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, Transplant, and Original Equipment Manufacturing (OEM). Werfen operates directly in more than 30 countries and more than 100 territories through distributors. For more information, visit werfen.com. 

Legal notice
This document contains forward-looking statements about our business, financial data, and events related to the prospects of Werfen. These forecasts can be identified by the use of words such as “expectation”, “vision”, “anticipation”, “intention”, “plan”, “belief”, “search”, “estimate”, “future”, “project”, or words with a similar meaning. We may also make projections in other reports, presentations, and press releases. Furthermore, our sales representatives may occasionally make forward-looking statements. These projections are based on our current expectations and on certain hypotheses, many of which are beyond the corporation’s control and subject to a series of risks and uncertainties. In the event that any of these risks or uncertainties should materialize or the underlying expectations are not fulfilled, the results or performance of Werfen may differ substantially (either positively or negatively) from those explicitly or implicitly forecast. Werfen assumes no obligation to update or revise any forward-looking statements made previously.